ABSTRACT
Objective To investigate the clinical efficacy and safety of bortezomib-based chemotherapy regimen [BTD chemotherapy regimen (bortezomib and thalidomide combined with dexamethasone) and BCD chemotherapy regimen (bortezomib and cyclophosphamide combined with dexamethasone)] in the treatment of new multiple myeloma (MM). Methods From May 2015 to May 2019, 80 newly diagnosed MM patients hospitalized in the Department of Hematology of Sanya Central Hospital were divided into BTD group (n=40) and BCD group (n=40). Patients in BTD group were given BTD chemotherapy regimen, and BCD group patients were given BCD chemotherapy regimen. Clinical efficacy, changes in myeloma markers [serum M protein, serum free light chain (κ-λ), immunofixation electrophoresis, β2 microglobulin, bone marrow plasma cells] and adverse reactions were evaluated in the two groups after 4 courses of treatment. Overall survival (OS) and progression-free survival (PFS) in the two groups were evaluated at follow-up period. Results The overall response rate (ORR) of the BTD group was significantly higher than that of the BCD group [95.0%(38/40) vs. 75.0%(30/40)], the difference was statistically significant (P0.05). Conclusion In the bortezomib-based chemotherapy regimen, the efficacy of BTD group is significantly better than that of BCD group, which could effectively reduce the indexes of myeloma, and the adverse reactions are lower, but there would be no significant difference in OS and PFS between the two groups.